The George Institute for Global Health is a not-for-profit global medical research institute established and headquartered in Sydney, with major centres in China, India and the UK, and an international network of experts and collaborators.
ViewThe Heart Research Institute (HRI) is an internationally recognised research institute that performs cutting-edge cardiovascular research. The main focus of this research is to gain an understanding of the development and progression of atherosclerosis, the dominant cause of cardiovascular disease.
ViewThe Malaghan Institute of Medical Research is New Zealand’s leading independent biomedical research institute, with a history spanning over five decades. The Institute’s research centers on the immune system, and how it may be harnessed to treat human disease. Pioneering research programmes explore fields of immunotherapy such as cancer, asthma and allergy, infectious diseases, gut health and brain health.
ViewThrough the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.